Positives

• PT-141 may be relevant only for patients whose Long COVID or ME/CFS includes distressing libido or sexual-function changes; sexual health can still matter for quality of life in chronic illness (Drugs.com).
• Clinical studies focus on sexual desire/arousal outcomes, not PEM, brain fog, dysautonomia, MCAS, or fatigue (PMC).

Negatives

• This should not be framed as a broad Long COVID or ME/CFS treatment; its main use case is sexual desire or arousal symptoms (World Journal of Men's Health).
• Nausea, flushing, headache, and blood-pressure effects may be poorly tolerated by medication-sensitive patients (PMC).

Hurdles & Side Effects

• Access depends on indication, prescribing comfort, and cost, and peptide-market versions are not equivalent to regulated medication (Mayo Clinic).
• Patients with cardiovascular issues, uncontrolled blood pressure, POTS, or migraine history should discuss risks carefully with a clinician (Long-Term Safety Study).